Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Acute lymphoblastic leukaemia, drawn from the whole corpus: 93 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Adult ALL outcomes.
CD19-negative relapse.
Background: MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
CD19-negative relapse after blinatumomab or CAR-T; CD22 and dual-antigen CARs are early.
Background: MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
T-cell ALL has no approved immunotherapy; CD7 CAR-T (fratricide) and venetoclax combinations are experimental.
Ph-like ALL (CRLF2, JAK) has poor outcomes and only trial access to JAK/ABL-class inhibitors.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Infant KMT2A-rearranged ALL still has EFS under 50% on chemotherapy alone.
Continuous-infusion blinatumomab is burdensome; subcutaneous formulation not yet approved.
Which adults can safely skip transplant after MRD-negative immunotherapy remission is untested in randomised trials.
Background: MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
Late effects of curative paediatric therapy (neurocognitive, cardiac, second cancers) and survivorship care.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Adults treated outside academic centres have markedly worse survival; access to CAR-T and paediatric-inspired protocols is uneven.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 59 changes by month →When this page itself was last checked or edited.
Paediatric-inspired regimens (CALGB 10403, GRAALL, UKALL) with asparaginase; blinatumomab consolidation (E1910); MRD-guided transplant. (NCCN Category 1 (blinatumomab consolidation))
Hyper-CVAD or age-adapted multi-agent chemotherapy with blinatumomab interleaved in consolidation (E1910); inotuzumab-containing lower-intensity regimens (Mini-hyper-CVD + InO ± blinatumomab) for older adults; MRD-driven transplant. (NCCN Category 1 (E1910 regimen))
Blinatumomab (BLAST; full approval 2018) to convert to MRD negativity, then transplant or continued blinatumomab-based therapy. (NCCN Category 1)
Ponatinib (PhALLCON) or dasatinib with reduced-intensity chemotherapy, or chemotherapy-free TKI + blinatumomab (D-ALBA); BCR::ABL1 PCR monitoring; transplant for MRD persistence or IKZF1-plus, increasingly omitted for MRD-negative patients. (NCCN Category 2A (ponatinib preferred TKI))
Blinatumomab (TOWER) or inotuzumab (INO-VATE) as salvage and bridge; CD19 CAR-T (tisagenlecleucel ≤25 years; obe-cel or brexucabtagene in adults) for second salvage or as definitive therapy; transplant for those not previously transplanted; CD22 or dual CAR-T for CD19-negative relapse in trials. (NCCN Category 2A)